Cargando…

Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients

BACKGROUND: This study aimed to evaluate the population pharmacokinetics of digoxin in Japanese patients and establish a dosage regimen based on the pharmacokinetic data. METHODS: We analyzed 287 serum digoxin samples from 192 individuals by using the nonlinear mixed effects model. We used simulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Toshiaki, Morita, Mami, Miyaji, Futaba, Inomata, Takayuki, Ako, Junya, Atsuda, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728823/
https://www.ncbi.nlm.nih.gov/pubmed/26819736
http://dx.doi.org/10.1186/s40780-015-0023-6
_version_ 1782412186614759424
author Komatsu, Toshiaki
Morita, Mami
Miyaji, Futaba
Inomata, Takayuki
Ako, Junya
Atsuda, Koichiro
author_facet Komatsu, Toshiaki
Morita, Mami
Miyaji, Futaba
Inomata, Takayuki
Ako, Junya
Atsuda, Koichiro
author_sort Komatsu, Toshiaki
collection PubMed
description BACKGROUND: This study aimed to evaluate the population pharmacokinetics of digoxin in Japanese patients and establish a dosage regimen based on the pharmacokinetic data. METHODS: We analyzed 287 serum digoxin samples from 192 individuals by using the nonlinear mixed effects model. We used simulations to optimize the dosage regimen of digoxin to achieve a high likelihood of the target concentration (0.5–0.8 ng/mL). RESULTS: The total body clearance (CL/F ([L/h]) was calculated using the following formula: CL/F = (1.21 + 0.0532 × CLcr [(mL/min]) × (1 + 0.787 × AMD), where CLcr is the creatinine clearance and AMD is 0 in the case of concomitant administration of amiodarone and 1 otherwise. To achieve the target concentration (0.5–0.8 ng/mL), the dosage of digoxin was 0.0625 mg/day (CLcr < 35 mL/min and AMD = 0); 0.125 mg/day (CLcr, 35–65 mL/min and AMD = 0); 0.1875 mg/day (CLcr, 65–100 mL/min and AMD = 0); 0.0625 mg/every other day (CLcr < 30 mL/min and AMD = 1); and 0.0625 mg/day (CLcr, 30–85 mL/min and AMD = 1). CONCLUSIONS: Our findings suggest that population parameters are useful for evaluating digoxin pharmacokinetics.
format Online
Article
Text
id pubmed-4728823
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47288232016-01-27 Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients Komatsu, Toshiaki Morita, Mami Miyaji, Futaba Inomata, Takayuki Ako, Junya Atsuda, Koichiro J Pharm Health Care Sci Research Article BACKGROUND: This study aimed to evaluate the population pharmacokinetics of digoxin in Japanese patients and establish a dosage regimen based on the pharmacokinetic data. METHODS: We analyzed 287 serum digoxin samples from 192 individuals by using the nonlinear mixed effects model. We used simulations to optimize the dosage regimen of digoxin to achieve a high likelihood of the target concentration (0.5–0.8 ng/mL). RESULTS: The total body clearance (CL/F ([L/h]) was calculated using the following formula: CL/F = (1.21 + 0.0532 × CLcr [(mL/min]) × (1 + 0.787 × AMD), where CLcr is the creatinine clearance and AMD is 0 in the case of concomitant administration of amiodarone and 1 otherwise. To achieve the target concentration (0.5–0.8 ng/mL), the dosage of digoxin was 0.0625 mg/day (CLcr < 35 mL/min and AMD = 0); 0.125 mg/day (CLcr, 35–65 mL/min and AMD = 0); 0.1875 mg/day (CLcr, 65–100 mL/min and AMD = 0); 0.0625 mg/every other day (CLcr < 30 mL/min and AMD = 1); and 0.0625 mg/day (CLcr, 30–85 mL/min and AMD = 1). CONCLUSIONS: Our findings suggest that population parameters are useful for evaluating digoxin pharmacokinetics. BioMed Central 2015-09-25 /pmc/articles/PMC4728823/ /pubmed/26819736 http://dx.doi.org/10.1186/s40780-015-0023-6 Text en © Komatsu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Komatsu, Toshiaki
Morita, Mami
Miyaji, Futaba
Inomata, Takayuki
Ako, Junya
Atsuda, Koichiro
Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title_full Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title_fullStr Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title_full_unstemmed Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title_short Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
title_sort population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728823/
https://www.ncbi.nlm.nih.gov/pubmed/26819736
http://dx.doi.org/10.1186/s40780-015-0023-6
work_keys_str_mv AT komatsutoshiaki populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients
AT moritamami populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients
AT miyajifutaba populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients
AT inomatatakayuki populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients
AT akojunya populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients
AT atsudakoichiro populationpharmacokineticsandoptimizationofthedosingregimenofdigoxininadultpatients